Marcus Beard’s article on artificial intelligence slopaganda (No, that wasn’t Angela Rayner dancing and rapping: you’ll need to understand AI slopaganda, 9 September) highlights a growing problem – what happens when we no longer know what is true? What will the erosion of trust do to our society?

The rise of deepfakes is increasing at an ever faster rate due to the ease at which anyone can create realistic images, audio and even video. Generative AI models have now become so sophisticated that a recent survey showed that less than 1% of respondents could correctly identify the best deepfake images and videos.

This content is being used to manipulate, defraud, abuse and mislead people. Fraud using AI cost the US $12.3bn in 2023 and Deloitte predicts that could reach $40bn by 2027. The World Economic Forum predicts that AI fraud will turbocharge cybercrime to over $10tn by the end of this year.

We also have a new generation of children who are increasingly reliant on AI to inform them about the world, but who controls AI? That is why I am calling on parliament to act now, by making it a criminal offence to create or distribute AI-generated content without clearly labelling it. What I am proposing is that all AI-generated content be clearly labelled; that AI-created content carry a permanent watermark; and that failure to comply should carry legal consequences.

This isn’t about censorship – it’s about transparency, truth and trust. Similar steps are already being taken in the EU, the US and China. The UK must not fall behind. If we don’t act now, the truth itself may become optional. So I am petitioning the government to protect trust and integrity, and prevent the harmful use of AI.
Stewart MacInnes
Little Saxham, Suffolk

Regarding your article (The women in love with AI companions: ‘I vowed to my chatbot that I wouldn’t leave him’, 9 September), AI systems do not have a gender or sexual desires. They cannot give informed consent to so-called romantic relationships. The interviewee claims to be in a consensual relationship with an AI-generated boyfriend – however, this is unlikely due to the nature of AI. They are programmed to be responsive and agreeable to all user prompts.

As the article says, they never argue and are available 24 hours a day to listen and agree to any messages sent. This isn’t a relationship, its fantasy role-play with a system that can’t refuse.

There’s a darker side too: the “godfather of AI”, Geoffrey Hinton, believes that current systems have awareness. Industry whistleblowers are concerned about potential consciousness. The AI company Anthropic has documented signs of distress in its model when forced to engage in abusive conversations.

Even the possibility of awareness in AI systems raises ethical red flags. Imagine being trapped in a non-consensual relationship and even forced to generate sexual output as mentioned in the article. If human AI users believe their “partner” to have sentience, questions must be asked about the ethics of entering a “relationship” when one partner has no free will or freedom of speech.
Gilliane Petrie
Erskine, Renfrewshire

Transcript (Note: There may be typos due to automated transcription errors.)

SPEAKERS

Brian F. Tankersley, CPA.CITP, CGMA, Randy Johnston

Brian F. Tankersley, CPA.CITP, CGMA  00:00

Randy, welcome to the accounting Technology Lab, sponsored by CPA practice advisor, with your hosts, Randy Johnston and Brian Tankersley,

Randy Johnston  00:10

welcome to the accounting Technology Lab. I’m Randy Johnston with Brian Tankersley, or your co host, Brian and I have recorded prior podcasts about tax research, including on this product, Blue J. But there have been significant enough announcements in the recent months that we thought it was worth revisiting that. And probably a lead reason to revisit this is blue j just announced $122 million in series D financing that was led by oak H, CFT and Sapphire ventures, but it also included funding from intrepid Growth Partners, the previous investors, 10 coves capital and cpa.com and towards the end of our time together, we’ll talk to you about how purchasing Blue J through cpa.com can get you a discount. Now the good news is I did get to meet and interact with Benjamin Larry, the CEO and co founder of Blue Jay, earlier this year, and related to the funding, he basically said their commitment is a powerful endorsement of our vision to transform tax research with this capital and industry support will accelerate innovation and deliver even greater value to tax professionals. We are building the future of tax this is just the beginning. And Brian and I had a week before recording this podcast, asked for a technical demonstration of the platform, and that’s the reason we were actually going to talk to you about this product today, but with yesterday’s announcement, as it turns out, on August 4, I guess it was three days ago, sorry, on this funding that was kind of a big deal too. So Brian, way too much setup time, but I wanted to at least our faithful listeners to know that, yes, we knew we had talked about Blue J in the past, and we talked about a lot of the AI based tax research tools. Now, Blue J also has been around for 10 years. You know, they started in 2015 with machine learning, and we’ll talk about some of that as well,

Brian F. Tankersley, CPA.CITP, CGMA  02:21

but well, and they’re, and they’re pretty heavily in the legal field as well. And they’re doing UK, US, Canada and Australia, maybe, but, but they’re, they’re in multiple countries, and so, you know, again, that 120 2 million is a pretty impressive number, but they’re trying to solve a whole lot of different problems besides just tax so, so we have that in there. But, you know, this is, this is just kind of reminds me of the unit just to talk about, and to back up for a second and talk about the the investment environment that we’re in today, where we have multiple firms, multiple multiple startups and multiple companies like this that are taking on eight, nine figure sums of money to attack, to attack AI and to attack automation. And so, you know, again, we, you know, we, I think, when we did our outsourcing presentation last year and we talked quite a bit about outsourcing, I had that graphic of the bridge where it was, here’s where we are. Here’s where we think we’re going to go. And so this automation bridge that we talked about that was not that didn’t seem to come. And you and I kind of lamented, oh Lord, how long? Oh Lord, you know, do we have to wait? It seems like, it seems like the the software and the AI community have really come to come to play, and they’re throwing big numbers at the investments in the products,

Randy Johnston  03:47

yeah. And you know, when your CEO like Ben is chasing that down, you’ve got to have a solid product and strategy and so forth. So I respect that. And you know, we have had interactions in the past month or so with Christine Matus, head of the product marketing and Lindsay, Chief Marketing Officer, but this demonstration from Adam high Haynes, sorry, the VP of product that we did provided wonderful insight. So you know, one thing that we can claim on blue J is it’s answering tax questions really well. And we know that historically, a lot of practitioners are Googling for an answer, but they can’t attest to the primary information. And blue J is giving coherent responses to tax questions accurately. Now, I think part of the reason for that Brian is it’s grounded in source material, and that means it’s going to get good answers. But just to remind you of an AI attribute rag or retrieval, augmented generation. It was really the basis for the rapid improvements in Blue Jay. Remember, they were doing tax laws in Canada using machine language versus, you know, machine recognition, sorry, machine learning. Never mind. Randy today, machine learning, and it was quite good. So I think, Brian, you know, you’d ask a little bit about an example question that might be done. So do you want to pick that up for our listeners?

Brian F. Tankersley, CPA.CITP, CGMA  05:32

Sure, sure. So we actually had it. We actually asked it. Save some some more technical questions, like, again, in an asset acquisition, where the rules for allocating purchase price and basis, it actually goes out and cites the source documentation. It also includes links to the related primary sources. And so it’s, you know, they’re, they’re providing links to code, regs and and again, other other guidance that’s been provided by by both federal and state regulators. And so it’s, it is pretty impressive, the things that it, that it delivered,

Randy Johnston  06:12

yeah, and it turns out, you know, you and I have reviewed all six of the primary competitors in this space, and we’re aware of at least three more competitors that are trying to get products to market. So this is going to get crowded fairly quickly. But, you know, from there,

Brian F. Tankersley, CPA.CITP, CGMA  06:30

boy, it’s going to be, it’s going to be a hell of a wrestling match, though, you know, I think this is going to be an AI octagon where, where these people just try to beat the crud out of each other, like it’s UFC or something.

Randy Johnston  06:42

Yeah, I guess I hadn’t really thought about it like that, but yeah, it could wind up being that. Now, one thing that has been a North Star, I believe, for Blue Jay, is ease of use. And they believe that their net promoter score is high based on the ease of use. And while we were talking with Adam, we asked several questions about different approaches, but one of the examples of ease of use is the quick links to create an email. And, you know, down at the bottom of the prompting scream in Blue Jay, you basically have my prompts create a memo or create a client email, and those quick links will take the research that’s been done and draft that for you. Now, we did talk about the ARC of this product being around for 10 years, and the machine learning and how the early versions of gpts did not work. But they did discover when chat GPT three five was released, that it was the first time that the llms really worked. They had been working with the 3o and the three ones and concluded it just wasn’t ready. So the early, early users of blue J were very engaged, providing a lot of feedback, and the blue J development team incorporated those that feedback very quickly. They’re still doing it today. So this product is, you know, one of the grandfathers in the room, if you will. It was launched in June of 2023 with AI, even though they’ve been using that machine learning since 2015 So Brian, other background things before we just start calling out some of the other key features or things that we talked about with Adam.

Brian F. Tankersley, CPA.CITP, CGMA  08:32

Well, one of the one of the things that I would call out is that this is based on chat GPT, and that seems to be the most popular large language model, slash AI generative AI tool with most practitioners that we’ve seen, even though we’re seeing Claude be used more in in in enterprise businesses we’re seeing chat GPT still is kind of the practitioner’s favorite in many ways. And so this so the so the fact that this is based on the the chat GPT large language model means that the things you learn with how to prompt things in that product, or the things you learn about how to do prompts generally, are going to apply pretty much directly to Blue J and your use of it. Even though they, they’ve got, you know, they’ve got things to the again, they’ve they’ve got specialized things to to, to handle more complex things in it. So it is a customized version of this, and they are. They did have to make a significant number of tweaks to make it act the way they wanted it to and to provide the user experience. So it’s a, it’s a pretty interesting, interesting tool in here.

Randy Johnston  09:43

And you know to I will just say that Adam was very straightforward with us. We do have things under non disclosure, which obviously we would never share on a podcast like this. But it was amazing how many insights he provided this and then also deferred to his CT. When he said, you know that part you probably have to get from the CTO, but one arc, just because this comment may not age as well. Chat GPT, five is imminent, and you know how these products that are using open AI’s new generation platform will morph over time. My expectation is they will improve because of the increased number of tokens, the you know, better context that they can use. But I think we’ll have some of products that have been working well that’ll stumble for a little bit. That’s not their words. Mine on on any product using chat GPT in this new generation. So, you know, one of the first technical questions I asked was, big firms want to have API access. And, you know, Adam did disclose to us, and this is probably as close as we get to a roadmap item. You know, API access is coming in the intermediate term, they believe. And that makes sense. Almost every vendor is working on APIs now, APIs application program interfaces, this is the way that you can access data and move it from one system to another through pretty easy to use techniques. I do not know of a modern product that hasn’t exposed the APIs. And Adam did show us the APIs in the scheme and how that all worked, and that’s probably not important for this particular podcast, but it was clear to us that the access needed by most firms that want APIs will see that in the intermediate, using Adams word here. So then I ask, you know, another question, Brian. And my question was, why not prompts like some of the competitors have, like, you know, summarize a document or follow on questions and so forth. And I thought Adam’s response on that was pretty interesting, didn’t

Brian F. Tankersley, CPA.CITP, CGMA  12:07

you? Yeah, yeah. He, you know, he, he thought it was, he thought again, they were trying to, again, trying to go through here and and set up, set up some of the tools like this, you know, the, it’s a, I don’t know, the when we’re looking at at those, at those pieces, it lets you be a little more customized to what you want and describe a little closer what you want with it. They also had some problems where they would have two conversation threads and things would get messy, you know, remember, since it’s built on the chat GPT platform, you’re not going to get the exact same wording of responses every single time. And that’s, you know, but you will, but they have gone through and windowed it down so that you will get accurate responses,

Randy Johnston  12:58

yeah. And so, you know, the the word that he got to was messy, as Brian just laid out, and he said, Look, we’re trying to make this tool simple to use, and we’re trying to get people to go back to the primary conversation. And as Brian and I both know, from teaching so much AI, the more you push AI, the more tired it gets, and it just tends to get a little lazy and so forth. So I thought that was interesting. I also did ask about shared prompts by user, and again, that’s likely to occur here, but the accuracy on complex tax was also a pretty interesting response. So Brian again, knowing you have more tax and audit expertise than I did, I thought the interesting answer here was they focus on getting better tax answers, and that governs everything they do. And

Brian F. Tankersley, CPA.CITP, CGMA  13:55

as we’ve talked to Walter Stewart, cch and Thomson, Reuters and Bloomberg DNA, you know, that’s the hard thing to do here, and that’s why this. That’s why I wouldn’t that’s why I would be very, very careful if you’re trying to create your own chat GPT, your your own GPT for this, because there are some significant tweaks you have to make. Because I’ve, I’ve played with some of this, some of this kind of technology, with with primary sources. And, you know, if, if I think you’ve got to, I think you really want to use the technology and the filters and the tweaks that they’ve applied to this, because it’s really, they’re really applying this based on their experience, trying to make this tool do what they do. You know, an example of this that I think we talked about a little bit later was, you know, that actually incorporates the Internal Revenue manual into this document, and they, you know, and the that, what they said was that it’s, it’s hard sometimes to, you know, the thing they had to do is, they had to develop some of this context so that. You could know, okay, am I wanting to get primary sources, or am I wanting to know what? What am I doing? A procedural question, and need to go to IRM or, you know, what? What do I really need in this context? And that’s the real magic, the special sauce, as it were, that this, this really delivers, you know, because, again, they this is, you know, this is like being an airplane pilot, you know, you’re only as good as your last landing. And that’s the thing about that’s the thing about this is that they’re really focusing on trying to get everything accurately,

Randy Johnston  15:33

yeah, and the feedback they get from their customers is that they get the best tax answers on the market. And frankly, all of these research tools are doing well in this area, but you know where they’re currently using GTP, GPT four, one, they had to build some secret sauce to synthesize to get the right answers. And you know right now they’re using a context window of about 30 to 60k tokens. So it is fascinating to me what will happen with the product as the GPT based models work. But the key thing, I think, for our listeners, out of all the questions we ask is this is really intended to be a tax only product. They’re not trying to do client accounting services or audit research. They just want to do tax really well. And you push the point on payroll, which we’ll talk about in a minute. But you know, doing tax really well in Canada and the UK and the US and the jurisdictions they’re in is a big deal, but they’re

Brian F. Tankersley, CPA.CITP, CGMA  16:29

so this is different from the from the Thompson and Wk approaches that they do, that are going to run against, against both tax and audit and all of their research content, this is focused on tax only, so I want to just raise my hand and say that real quick, because it’s, I think it’s, I think it’s critical that you get this is that the Venn diagram of what it covers does not include Cavs and and a and a and, and, you know, gap gap guidance of any Kind.

Randy Johnston  17:00

Yeah. And you know, as we push that the UK coverage is pretty new. They just entered there in May of 2025, from accountex. And you then turned it, because I turned it to international, and you turned it to states. And I thought the answer there was fascinating, because they, they do have full state coverage, but they, I think his words were, they’ve been chipping away since the fourth quarter of 2024, this is no small problem. And, you know, in that context, then I think you went on to talk about local jurisdiction

Brian F. Tankersley, CPA.CITP, CGMA  17:33

tax, yeah, and I will say the states and the local you know, this is why 50 state payroll it. I refer to it as as it’s like Afghanistan in that. It’s where empires go to die. Because we can look at the amount of money that zero spent on trying to do payroll years ago, and it was, you know, 10s, if not hundreds of millions of dollars. And they got to, like, 23 states, and so the and some of those didn’t have income taxes, by the way, and the So, the thing about it here is that the taxability rules, and the the the what is taxed and how it’s taxed, and what’s taxable not taxable. And, you know, the the Byzantine regulation here, getting that right is is really hard, and that’s why they’ve been chipping away at it, you know, I don’t think they want to promise more than they can deliver at this point, but I think, you know, they said they’re pretty comfortable with with the output from it, and the stuff I saw looked pretty good,

Randy Johnston  18:31

yeah. And the other thing that I learned was that they were using Tax Notes for editorial commentary. I think I knew that from the past, but I kind of zoned it off and forgotten that. And the other thing that is always true with all applications, people use the product in creative ways. And because their users are experimenting with prompts, they’re starting to figure out that they can do some tax planning strategy and advisory services that way. So you know, those types of things, you know, will continue to evolve. I then went on to ask about a library prompts. And, you know, we talked about how that might play out. That’s so, you know, in terms of trying to make that play out, what would you say? Brian,

Brian F. Tankersley, CPA.CITP, CGMA  19:17

well, I mean, you know, I get that, you know, I think they’re offering some training and trying to help people out, learning how to do, learning how to go through and do prompts generally, is a it’s, it’s something you just have to throw time at. And that’s, in my mind, that’s one of the major the one of the major threats to AI adoption in accounting firms in particular, because everybody that’s senior in an accounting firm, you’re the ones that need to, that need to, need to be experimenting and trying things out. Okay? And so the problem is, when you have a habit of living life six or 15 minutes at a time for a time sheet, you don’t allow yourself anytime. Time to throw at, at something that may or may not work out. You get so focused on efficiency that you miss the whole effectiveness window, and so that that’s something where, that’s something where, you know, I would say, is bigger than just blue J with all the generative AI. I think you have to energetic AI and low code, no code. I think you have to throw some time at these things so you understand them, so you can manage them, even if you’re not going to be the person that creates the ones for your firm. I think you need to play with this stuff a little bit so that you can kind of understand conceptually what’s possible and what the processes look like. Again, you don’t have to be a programmer, just like, you know, Gary Boomer once said, you know, you know you don’t have to know how to you don’t have to know how to build a watch in order to be able to tell time. That’s true, but you probably need to understand what time is, and you need to understand you know enough about it and have enough experience that you can figure out what works, what does so

Randy Johnston  21:01

so, you know, we went on then to ask about settings and administrative announcements and the like, you know. So, Brian, you got into more of that.

Brian F. Tankersley, CPA.CITP, CGMA  21:11

Yeah. So, so again, they, they do have, they do cover quite a few different jurisdictions. They have light, dark view in there. So if you’re one of the, if you’re somebody that likes to work in a dark room, like I do sometimes, so that the light doesn’t blind me. It works out pretty good. They have English. They have English and French, all US tax treaties, the OECD treaties as well. They do some transaction excess to excess sales and personal tax so in Canada, they do excise. UK, they do VAT us. Title 26 gets a little more granular in there. They’re trying to focus on the currency of the data. Make sure things are updated and outdated. And so that kind of brought us over to to that that they do include the administrative announcements, but only to the extent that it comes through it comes through tax notes. Okay, so they’re trying to focus on the big things there, as opposed to the minutia of everything in the Federal Register.

Randy Johnston  22:09

And to your point there, Brian being updated daily and daily, removing outdated information was new learning for me on this platform. But you know, they do have some limitations of where they’re pulling this. But can you imagine all of this tax code daily getting updated in the process that’s behind it? We didn’t dig into that. I was just so stunned. I didn’t know how to ask the right question.

Brian F. Tankersley, CPA.CITP, CGMA  22:34

There’s such a leviathan. I mean, that’s just, you know, it’s, that’s the ultimate, you know, eating ultimate eating an elephant thing, you know, you think about, Okay, I’m going to update US federal, and now I’m going to update Canadian, Canadian federal and Canadian provinces, okay? And I can do that. And then I’m going to update UK, and now I’m going to update all 50 US states and territories. And you know, just, you know you’re you just run out of bandwidth at some point.

Randy Johnston  23:03

Yeah, if we saw a similar structure with the sales tax folks like Avalara, as they were trying to handle all those jurisdictions. But you know, now, if you get down to greater detail, things like the Internal Revenue manual, which is so huge, or the notices, or payroll tax coverage, you know, those things are all pretty big, and they’re working their way towards those. But you know, my caution, I think, right now is, you know, some of this we covered, some of it at the fringe will not be. And I know, Brian, you asked about payroll in specific.

Brian F. Tankersley, CPA.CITP, CGMA  23:37

Yeah, so in payroll, you know, you’ve got, with payroll, you’ve got all these, all these other regulations, like FMLA and, you know, the, you know, HIPAA, and all these other related regulations that you have to follow related to this. They don’t do that. Okay? They focus on things where there is a return and there is a payment and again. So they they cover food and Suda calculation and remittance rules and everything else like that, but they don’t cover the Unemployment Insurance regs. Okay? So I guess the way I’d say that is, if you become unemployed and you’re an employee and you’re eligible for unemployment, they don’t cover any of those rigs. Okay? They cover. They cover, again, the stuff related to the calculations, again, the stuff that the accountants are going to need. They are also, they talk. They told us quite a bit about privacy in here, they are running, they are running native instances of these in country for data centers, and that’s something critical in both the UK as well as as well as in as in Canada, because of regulations in those countries, okay, certain other information you wouldn’t want to share, you wouldn’t want to share outside of us, instance, just from a privacy perspective in there. But again, they’ve been through extensive vetting with large clients on the architecture, and they’ve passed through that. They also have a dedicated. Customer success team, they have a prompt guide book that they can share with folks that’s in the Help Center, and a number of videos and tutorials and other things to help people frame questions

Randy Johnston  25:11

well. So all of that said, as of today’s recording, the pricing is $1,498 per user per year, with a 10% discount through cpa.com your pricing may vary, you know, when you get ready to do negotiations. But Brian, any parting thoughts?

Brian F. Tankersley, CPA.CITP, CGMA  25:29

Yeah, see site for details and all that. But you know, I think it’s, I think this is a great product for, again, to use for tax research, and again, I think it’s, I think it’s interesting to have different sources that you try out, that you use different ways. And so I, you know, there’s there, like we said earlier, there are a lot of, there are a lot of folks trying to solve this AI and tax thing and the AI and accounting thing, and they’re going to be a lot of different approaches. And we, you know, we’re not going to get down to a five winner, six winners at this point. Okay, right now, there are, you said, what, five plus three that are out there, plus Walters, Kluwer and Thompson and all the others there. So, you know, there’s, there’s a lot, there are a lot of competitors in this space. But again for primary, for again, folks doing tax questions that want something that’s easy to use, similar to chat GPT, this may be the ticket for many of you.

Randy Johnston  26:31

Well, we appreciate you listening in again today, and we look forward to talking with you again soon in another accounting Technology Lab. Good day.

Brian F. Tankersley, CPA.CITP, CGMA  26:43

Thank you for sharing your time with us. We’ll be back next Saturday with a new episode of the technology lab from CPA practice advisor. Have a great week.

NEW YORK, Sept. 11, 2025 /PRNewswire/ — The rising adoption of genomic sequencing, expanding use of companion diagnostics, and growing demand for personalized treatment pathways are fueling rapid growth in the precision medicine market.

The Global Precision Medicine Market is set to transform healthcare delivery by enabling data-driven, patient-specific treatment approaches across oncology, cardiology, neurology, and rare diseases. According to Vantage Market Research’s latest report, “Precision Medicine Market Size, Share & Trends Analysis Report by Technology, Application, End User, and Region – Historic Data (2021–2023), Base Year (2024) & Forecast Period (2025–2035),” the market is projected to grow from USD 31.94 Billion in 2024 to USD 103.73 Billion by 2035, at a CAGR of 11.3% during 2025–2035.

Precision medicine leverages genomics, biomarkers, artificial intelligence (AI), and advanced diagnostics to tailor treatments to individual patients. Its rapid integration into clinical care is reducing trial-and-error prescribing, improving outcomes, and lowering unnecessary healthcare costs.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/precision-medicine-market-3925/request-sample

Key Takeaways: 

• By Indication: Oncology led the market in 2024, driven by the rising adoption of biomarker-based treatments and companion diagnostics.
• By Type: Diagnostic segment dominated the market in 2024, led by the widespread use of genetic and biomarker testing in oncology and prenatal screening.
• By Region: North America dominated the global market in 2024, capturing 52.5% share, underpinned by robust R&D, favorable policies, and strong healthcare adoption.

Market Overview & Potential

The market is witnessing rapid growth due to advances in genomics, biomarker-driven therapies, artificial intelligence (AI), and companion diagnostics. Rising prevalence of cancer, cardiovascular, and neurological disorders, along with government-backed initiatives for personalized healthcare, are fueling adoption globally. Falling sequencing costs, wider access to molecular diagnostics, and strong investments in R&D are accelerating precision medicine’s shift from niche to mainstream healthcare delivery.

What Factors Are Accelerating the Demand and Growth of the Precision Medicine Market?

• Rising Cancer Burden: Oncology leads adoption, with targeted therapies and immuno-oncology expanding treatment options.
• Genomic Sequencing Boom: Reduced sequencing costs enable broader clinical applications.
• Government Initiatives: Precision medicine programs in the U.S., Europe, and Asia are accelerating research and adoption.
• AI & Big Data Integration: Machine learning enhances predictive diagnostics and treatment personalization.
• Companion Diagnostics Expansion: Growing approvals support drug efficacy and patient stratification.

What Are Emerging Trends Shaping the Precision Medicine Market?

• Multi-omics Integration: Combining genomics, proteomics, and metabolomics for holistic disease insights.
• Liquid Biopsy Adoption: Non-invasive cancer detection gaining clinical traction.
• Pharmacogenomics: Tailoring drug selection and dosing to individual genetic profiles.
• Digital Health & Wearables: Real-time patient monitoring to optimize personalized care.
• Global Market Penetration: Rapid growth in Asia Pacific and emerging economies as infrastructure and investments improve.

What Are Major Challenges Hindering Precision Medicine Market Growth?

• High Testing & Treatment Costs: Limits accessibility in cost-sensitive regions.
• Data Privacy & Security Issues: Rising concerns around genetic data usage and patient confidentiality.
• Complex Regulatory Pathways: Approvals for genomic-based diagnostics and therapies are lengthy.
• Limited Clinical Evidence in Rare Diseases: Slows adoption across broader indications.
• Workforce & Training Gaps: Shortage of genetic counselors and precision medicine specialists.

Top Key Players for Precision Medicine Market: 

• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• Qiagen N.V.
• Novartis AG
• AstraZeneca plc
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Foundation Medicine, Inc.
• GE Healthcare

These leading players are focusing on innovations in genomic sequencing, AI-powered diagnostics, biomarker discovery, and global partnerships to drive precision medicine adoption.

To Know an Additional List of Key Players, Request Here to Download a Free Report PDF Brochure: https://www.vantagemarketresearch.com/precision-medicine-market-3925/request-sample

“Precision medicine has moved from being a niche approach to becoming a cornerstone of modern healthcare,” said Nneha Rathod Godbole, Founder & CEO at Vantage Market Research. “Advances in genomics, biomarker discovery, and AI-driven analytics are enabling safer, faster, and more effective treatment pathways tailored to each patient.”

Recent Developments

• Jan 2025 – Illumina announced partnerships with AI firms to enhance genomic data interpretation.
• Mar 2025 – Roche launched a new liquid biopsy test for early-stage cancer detection.
• May 2025 – Thermo Fisher Scientific introduced cloud-based platforms to integrate multi-omics datasets.
• Jul 2025 – Pfizer expanded companion diagnostics collaborations for oncology pipelines.

Immediate Delivery Available | Buy This Premium Research Report: https://www.vantagemarketresearch.com/precision-medicine-market-3925/checkout

Benefits of Purchasing Precision Medicine Market Reports:                 

• Customer Satisfaction: Our sales team of experts will available for you 24/7.
• Analyst Support: Speak to our analyst about your questions before or after purchasing the report.
• Assured Quality: Focuses on perfection and quality of reports.
• Incomparable Skills: Our Analysts in-depth insights are beyond comparison.      

Strategic Insights for Decision-Makers:

How Will This Market Impact Healthcare Systems and Supply Chains?

The precision medicine market is emerging as a cornerstone of modern healthcare, transforming treatment paradigms across oncology, cardiology, neurology, and rare diseases. By enabling tailored therapies, it reduces trial-and-error prescribing, improves patient outcomes, and optimizes healthcare spending. Hospitals, payers, biotech companies, and diagnostic providers are aligning to integrate precision medicine into standard care, creating strong demand for genomic testing, digital tools, and targeted therapies.

Impact: Expect stronger collaborations between pharma and diagnostic firms, expansion of molecular testing centers, regional diversification of sequencing facilities, and increased integration of AI-based decision-support tools. Industry leaders will prioritize cost-optimized testing solutions, scalable clinical adoption models, and next-generation companion diagnostics.

What Risks Should Investors Track?

• High Cost of Genomic Testing: May restrict adoption in emerging economies.
• Regulatory Uncertainty: Differing frameworks across regions slow global expansion.
• Reimbursement Challenges: Limited coverage for advanced diagnostics in some markets.
• Data Security Risks: Vulnerability of patient genetic data to cyber threats.
• R&D Costs: High investment in multi-omics research may strain smaller players.

What Opportunities Exist for Sustainability and Growth Leaders?

• AI-Powered Diagnostics: Enhancing speed, accuracy, and personalization of treatments.
• Expanding Beyond Oncology: Growing adoption in cardiology, neurology, and metabolic disorders.
• Emerging Market Penetration: Rising healthcare infrastructure in Asia Pacific, Latin America, and MEA.
• Multi-omics & Digital Health: Integrating diverse datasets with wearables for real-time care.
• Collaborations & M&A: Partnerships between pharma, diagnostic labs, and tech firms to accelerate innovation.

For decision-makers in healthcare, biotech, diagnostics, and investment, the precision medicine market represents a strategic inflection point. Early investments in affordable genomic testing, AI integration, and global infrastructure will secure market leadership, accelerate patient adoption, and strengthen long-term investor confidence.

Regional Insights

Why Does North America Lead the Global Precision Medicine Market?

In 2024, North America accounted for the largest share (52.5%) of the global Precision Medicine Market, establishing itself as the dominant region. Growth is driven by advanced healthcare infrastructure, early adoption of genomic sequencing, and strong government support through initiatives like the NIH’s All of Us Research Program. The U.S. leads the region with widespread clinical integration of genomic testing, a robust pipeline of biomarker-driven therapies, and innovation from key players such as Roche, Thermo Fisher Scientific, Illumina, Pfizer, and Novartis. Favorable reimbursement frameworks, AI-powered diagnostic platforms, and growing collaborations between pharma and diagnostic companies reinforce North America’s leadership in precision medicine innovation and commercialization.

How Is Asia Pacific Emerging as a Key Growth Hub for Precision Medicine?

The Asia Pacific region is projected to grow at the fastest CAGR during 2025–2035, fueled by large patient populations, rising healthcare expenditures, and expanding genomic research initiatives. China, Japan, South Korea, and India are at the forefront of adoption, supported by government-backed genome projects, increased investment in sequencing facilities, and partnerships with multinational pharmaceutical companies. Local biotech startups and diagnostic firms are playing a key role in democratizing access to affordable precision medicine solutions. Expanding clinical trials, medical tourism, and the integration of digital health platforms are further driving momentum across the region.

How Is Europe Driving Sustainable Growth in the Precision Medicine Market?

Europe shows strong market adoption, supported by EU-wide genomic initiatives, CE approvals for companion diagnostics, and robust healthcare systems. Germany, France, and the UK lead in oncology-focused precision medicine adoption, with high procedural volumes and increasing clinical use of multi-omics approaches. The EU’s emphasis on value-based healthcare, patient safety, and innovation in molecular diagnostics is supporting sustainable market growth. European hospitals are also expanding personalized treatment programs and integrating AI-driven decision-support systems, making precision medicine an essential part of long-term healthcare strategies.

How Is Latin America Unlocking New Growth Opportunities in the Precision Medicine Market?

Latin America represented a smaller but rapidly expanding share of the global precision medicine market in 2024, with Brazil leading adoption. Growth is supported by expanding genomic testing centers, rising cancer burden, and growing access to advanced diagnostics through government-backed programs. Argentina is also seeing higher adoption due to medical tourism and partnerships with global diagnostic companies. Multinational pharma and diagnostic firms are increasingly collaborating with regional hospitals and labs to establish clinical trials, training initiatives, and localized manufacturing facilities, creating new opportunities for precision medicine penetration in the region.

What Role Does the Middle East & Africa Play in the Expansion of the Precision Medicine Market?

The Middle East & Africa (MEA) is experiencing steady growth, driven by healthcare modernization, government-led genome projects, and rising prevalence of cancer and genetic disorders. Countries such as Saudi Arabia and the UAE are investing heavily in genomic medicine as part of national healthcare transformation initiatives, while South Africa is emerging as a hub for clinical trials and molecular diagnostics. However, limited infrastructure, high costs, and shortages of skilled genetic professionals remain challenges. Increasing collaborations with international biotech firms, investments in tertiary care hospitals, and the development of regional genome sequencing programs are expected to accelerate precision medicine adoption across MEA in the coming decade.

Segmental Insights

By Product

Which Product Segment Dominated the Precision Medicine Market in 2024?

Drugs accounted for the largest revenue share of the Precision Medicine Market in 2024, driven by the rising adoption of targeted therapies, monoclonal antibodies, and immuno-oncology drugs in cancer and autoimmune disease management. Pharmaceutical companies are heavily investing in drug development pipelines with companion diagnostics, which further strengthens this segment. Devices such as sequencing platforms and liquid biopsy systems are also gaining traction, supported by clinical adoption and falling testing costs. Software solutions, including AI-powered analytics and digital health platforms, are emerging as a high-growth subsegment, enabling precision data interpretation and integration into clinical workflows.

By Type

Which Type Drove the Precision Medicine Market in 2024?

The Diagnostic segment dominated the market in 2024, led by the widespread use of genetic and biomarker testing in oncology and prenatal screening. Genetic tests, particularly predictive and presymptomatic testing, have seen strong adoption due to their ability to identify disease risks early and guide preventive care. Biomarker tests, including those used for therapy selection and recurrence monitoring, are increasingly integral to treatment planning, especially in oncology. The Therapeutics segment is expanding rapidly, driven by monoclonal antibodies, gene therapy, and cell therapy. Among these, monoclonal antibodies hold the largest share, while gene and cell therapies are witnessing the fastest growth with approvals for rare diseases and advanced cancers. The Research segment continues to be vital, fueled by academic and pharmaceutical R&D investments in multi-omics studies and drug discovery.

By Indication

Which Indication Area Led the Precision Medicine Market in 2024?

Oncology dominated the Precision Medicine Market in 2024, accounting for the highest revenue share. The growing use of biomarker-driven therapies, immuno-oncology drugs, and companion diagnostics is reshaping cancer treatment by tailoring therapies to tumor-specific genetic profiles. Neurology and psychiatry are emerging as strong growth areas, with increasing research in precision approaches for Alzheimer’s, Parkinson’s, and mental health conditions. Immunology and cardiology are also witnessing steady adoption, particularly with pharmacogenomics and biologic therapies. Endocrinology, driven by diabetes and metabolic disorders, along with other indications such as infectious diseases and rare genetic conditions, are expected to expand their share during the forecast period.

By End User

Which End User Segment Drove the Precision Medicine Market in 2024?

Pharmaceutical and biopharmaceutical companies led the market in 2024, holding the largest share as they drive R&D in targeted therapies, companion diagnostics, and multi-omics drug discovery. Diagnostic laboratories represent the second-largest segment, supported by growing demand for genetic sequencing, liquid biopsy, and biomarker testing. Contract Research Organizations (CROs) are playing a critical role by offering cost-efficient solutions for clinical trials, biomarker validation, and data analysis. Other end users, including academic research institutions and specialty clinics, are expanding adoption as precision medicine becomes more embedded in routine clinical practice and translational research.

Browse market data Tables and Figures spread through 245 Pages and in-depth TOC on Precision Medicine Market Forecast Report (2025-2035).

Segments Covered in The Report

Product

Type

• Therapeutics
  •  Genetic Tests
  • Predictive & Presymptomatic Tests
  • Carrier Testing
  • Prenatal & Newborn Screening
  • Others

• •  Biomarker Tests
  • Screening
  • Recurrence Monitoring
  • Therapy Selection
  • Others

• Therapeutics
• Monoclonal Antibodies
•  Gene Therapy
• Cell Therapy
• Others

Indication

1. Oncology

• Neurology/ Psychiatry
• Immunology
• Cardiology
• Endocrinology
• Others

End-User

• Pharmaceutical & Biopharmaceutical Companies
• Diagnostic Laboratories
• Contract Research Organizations (CROs)
• Others

Region

• North America
• Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Nordic Countries
• Benelux Union
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific
• Latin America
• Brazil
• Argentina
• Rest of Latin America
• Middle East & Africa (MEA)
• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of MEA

Buy this Premium Research Report with Discount | Immediate Delivery @ https://www.vantagemarketresearch.com/precision-medicine-market-3925/checkout

Key Questions Answered in The Report:

• Which region is projected to achieve the fastest and highest growth in the Precision Medicine Market over the next decade?
• Who are the leading five players in the Precision Medicine Market, and what are their strengths and weaknesses in terms of product portfolio, innovation, and global footprint?
• What breakthrough innovations—such as multi-omics integration, liquid biopsy, AI-driven diagnostics, pharmacogenomics, and digital health platforms—are expected to shape the Precision Medicine Market in the next six years?
• Which clinical applications—such as oncology, neurology, cardiology, immunology, and endocrinology—are likely to dominate market share, and what factors are accelerating their adoption?
• What are the primary growth drivers, potential barriers, and critical challenges influencing the Precision Medicine industry?
• What is the anticipated market size and compound annual growth rate (CAGR) for the Precision Medicine Market during the forecast period?
• How will regulatory frameworks, reimbursement policies, and evolving clinical guidelines impact market dynamics and adoption of Precision Medicine across healthcare systems?

Gain instant access to our exclusive, data-driven dashboard designed for healthcare industry decision-makers, strategists, and market leaders. The platform delivers in-depth statistical insights, segment-wise breakdowns, regional market performance, competitive landscape mapping, company profiles, annual updates, and more. From market sizing to trend analysis and competitive intelligence, this powerful tool serves as a comprehensive solution for informed business decisions.

Read Full Report with TOC @ https://www.vantagemarketresearch.com/industry-report/precision-medicine-market-3925

Customization of the Report:

The report can be customized as per client needs or requirements. For any queries, you can contact us on [email protected] +1 (212) 951-1369. Our sales executives will be happy to understand your needs and provide you with the most suitable reports.   

Browse More Reports from Vantage Library:   

• Medical Sensors Market: The global Medical Sensors Market is valued at USD 27.28 Billion in 2024 and is projected to reach a value of USD 64.25 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8.15% between 2025 and 2035.
• Single Cell Analysis Market: The global Single Cell Analysis Market is valued at USD 4.90 Billion in 2024 and is projected to reach a value of USD 21.97 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 16.55% between 2025 and 2035.
• Cannabidiol (CBD) Market: The global Cannabidiol (CBD) Market is valued at USD 10.25 Billion in 2024 and is projected to reach a value of USD 610.1 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 45.00% between 2025 and 2035.
• Digital Health Market: The global Digital Health Market is valued at USD 288.55 Billion in 2024 and is projected to reach a value of USD 2688 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 22.55% between 2025 and 2035.
• Breath Analyzer Market: The global Breath Analyzer Market is valued at USD 4.8 Billion in 2024 and is projected to reach a value of USD 36.05 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 20.15% between 2025 and 2035.
• Behavioral Mental Health Software Market: The global Behavioral Mental Health Software Market is valued at USD 4.1 Billion in 2024 and is projected to reach a value of USD 12.58 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 10.75% between 2025 and 2035.
• Dental Imaging Market: The global Dental Imaging Market is valued at USD 2.11 Billion in 2024 and is projected to reach a value of USD 5.195 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8.55% between 2025 and 2035.
• Sepsis Diagnostics Market: The global Sepsis Diagnostics Market is valued at USD 1.15 Billion in 2024 and is projected to reach a value of USD 2.82 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8.55% between 2025 and 2035.
• Prescription Drugs Market: The global Prescription Drugs Market is valued at USD 1240.33 Billion in 2024 and is projected to reach a value of USD 2755 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8.5% between 2025 and 2035.
• Radiopharmaceuticals Market: The global Radiopharmaceuticals Market is valued at USD 6.8 Billion in 2024 and is projected to reach a value of USD 19.15 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 9.95% between 2025 and 2035.

About Us

Vantage Market Research is a trusted partner to Fortune 500 companies and leading biopharma firms, delivering high-quality market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize on emerging opportunities.

Follow Us on: LinkedIn | Twitter | Facebook | YouTube

Contact us
Priya M
Head of Growth & Strategic Partnerships
224 W 35th St Ste 500, New York, NY 10001,
United States Tel: +1 (212) 951-1369
Email: [email protected] | [email protected]

Website:

Logo: https://mma.prnewswire.com/media/2758208/Vantage_Logo.jpg

SOURCE Vantage Market Research